NEW YORK – Strata Oncology on Wednesday said it will soon begin enrollment in the Sentinel trial, in which the Michigan-based precision oncology company will evaluate its investigational liquid biopsy assay in patients with solid tumors to determine if the test can detect disease recurrence and monitor treatment effectiveness.
Enrollment in the prospective, observational trial, which will eventually include around 100,000 cancer patients with stage 1 to stage 3 solid tumors, is slated to start in the first half of 2021. The trial will identify patients' cancer mutation profile first using the StrataNGS, the company's DNA and RNA tissue-based molecular profiling test, and then use the results to develop a highly sensitive and specific personalized liquid biopsy test that gauges patients' tumor alterations.
Strata hopes the assay will help guide treatment decisions for patients with early-stage tumors. "To date, most advances in precision oncology have been in late-stage cancer," Dan Rhodes, CEO of Strata Oncology, said in a statement. "The clinical and molecular information generated in this study has the potential to advance precision cancer care to the early stage."
The company has also partnered with several pharmaceutical companies to identify patients for clinical trials using StrataNGS. It additionally offers companies a clinical trial platform and provides real-world data. In the past year, Strata has partnered with Mirati Therapeutics, BioMed Valley Discoveries, and Elevation Oncology to screen patients for their clinical trials.